<DOC>
	<DOCNO>NCT02815644</DOCNO>
	<brief_summary>The trial perform open-label , randomised , single-dose , two-sequence crossover design assessment effect food bioavailability empagliflozin / linagliptin fix dose combination ( FDC ) tablet .</brief_summary>
	<brief_title>Empa/Lina FDC Food Effect Study ( Japan )</brief_title>
	<detailed_description />
	<mesh_term>Empagliflozin</mesh_term>
	<mesh_term>Linagliptin</mesh_term>
	<criteria>Inclusion criterion : Healthy male subject age &gt; =20 &lt; =45 year ; body weight : &gt; =50 kg &lt; =80 kg ; body mass index : &gt; =18.0 &lt; =25.0 kg/m2 Without clinically significant finding complication basis complete medical history , include physical examination , vital sign ( blood pressure ( BP ) , pulse rate ( PR ) , body temperature ) Signed date write informed consent prior admission trial accordance Good Clinical Practice ( GCP ) local legislation Exclusion criterion : Any find medical examination ( include blood pressure , pulse rate electrocardiogram ) deviate normal clinical relevance Further exclusion criterion apply</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>